Wittenberg Investment Management, Inc. Immunovant, Inc. Transaction History

Wittenberg Investment Management, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$3.93 - $6.37 $261,352 - $423,617	-66,502 Reduced 38.22%	107,498 $600,000
Q2 2022 Aug 15, 2022	BUY	$3.38 - $5.65 $113,230 - $189,275	33,500 Added 23.84%	174,000 $679,000
Q3 2021 Nov 05, 2021	BUY	$7.01 - $11.37 $536,265 - $869,804	76,500 Added 119.53%	140,500 $1.22 Million
Q2 2021 Aug 12, 2021	BUY	$9.4 - $16.85 $601,600 - $1.08 Million	64,000 New	64,000 $676,000

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Wittenberg Investment Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Wittenberg Investment Management, Inc. with notifications on news.